Ablating ERO1A in various syngeneic mouse models of cancer (colorectal, lung, and melanoma) impaired activation of the IRE1α-XBP1s pathway, induced immunogenic cell death, and enhanced the efficacy of anti-PD-1 therapy. This evidence concerns the gene PDCD1 and melanoma.